Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Paradigm Biopharmaceuticals Ltd. ( (AU:PAR) ).
Paradigm Biopharmaceuticals Ltd has announced the launch of its Loyalty Options Offer and Piggyback Options Offer, aimed at rewarding shareholders and providing further growth opportunities. The initiative is designed to support the company’s financial needs for its Phase III Clinical Trials, with potential fundraising of over $111 million if all options are exercised. This move underscores Paradigm’s commitment to advancing its clinical programs and fostering shareholder engagement.
More about Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd is a late-stage drug development company focused on delivering new therapies to address unmet medical needs.
YTD Price Performance: 22.96%
Average Trading Volume: 3,620
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $134.3M
For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.
